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Da minority (in our population, planned on-pump revascular-
ization was limited to 56 of 400 patients, 13.5% of the total),
they were the patients who would have benefited more from
the protocol. Second, the lack of long-term follow-up could
miss some late complications that were not evident at 45
days. Third, possible interactions with other drugs (eg,
beta-blockers) were not investigated, and the effect of in-
creased perioperative oxygenation that might reduce the
stimulus for endogenous erythropoietin production, making
exogenous erythropoietin a more desirable option, was not
taken into account. Finally, because of their lack of availabil-
ity in Italy, neither aprotinin nor Amicar was used as part of
the multifactorial blood-sparing strategy.
CONCLUSIONS
High-dose HRE administration, even in the very short
term, leads to a significant reduction in transfusion rate
and a significant increase in Hb values, thereby almost halv-
ing the risk of allogenic blood transfusion. No adverse
events related to HRE administration were recorded. A
very short preoperative administration of HRE seems to be
a safe and easy method to reduce the need for allogenic
blood transfusion and may be considered as part of a multi-
factorial strategy toward a further reduction for the need of
transfusion in heart surgery.
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Dr Colleen Koch (Cleveland, Ohio). You present intriguing
data demonstrating reduced red cell transfusion in patients receiv-
ing very short-term use of erythropoietin. I have 3 questions for
you, and they pertain to the timing of administration, adverse
events, and cost.
The first is with regard to timing. One of the biggest hurdles for
the use of erythropoietin in the cardiac surgical setting is the short
time interval between patient evaluation and the eventual operation.
You demonstrated feasibility and effectiveness for reducing red cell
transfusion as well as increasing day 4 hemoglobin. My question
for you is, what were your indications for transfusion in this study?
Meaning, was there a transfusion policy such that patients who
were in your control group and erythropoietin group had a similar
hemoglobin trigger that initiated a red cell transfusion?
Dr Weltert. Yes, of course we have a transfusion policy. We
transfuse when the patient’s hemoglobin decreases to less than 8
g/dL in the absence of symptoms and when blood exsanguination
as estimated by saturation of venous blood decreases to less than
50% even with optimal hemoglobin values, and, of course, this
policy did not differ between the 2 groups.
Dr Koch.Wonderful. Now, my second question pertains to ad-
verse events, and one of the major concerns with the use of eryth-
ropoietin in the cardiac surgical setting is the risk of thrombosis and
thromboembolism. You reported no increase in risk of thrombosis
or thromboembolism for those patients who received erythropoie-
tin. Of note, in the United States the Food and Drug Administration
has not approved erythropoietin for the specific use of decreasing
red cell transfusion in cardiac surgery. So my question is, why do
you think you did not find an increased risk for thrombosis? Is there
some way you manage the patients differently, anticipating that this
might be a risk for complications?
DrWeltert.Good question. It was a surprise to us as well to find
no complication at all. A few minor complications have been
reported, such as rash, dizziness, fatigue, and a low incidence of
thrombosis. So we expected to find some, approximately 1%. As
I said, we had absolutely no adverse event.ery c March 2010
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DOne possible explanation, one possible pitfall of the study is that
we ended the follow-up on day 4. So we can’t ascertain if some-
thing has happened after discharge. I can tell you now confiden-
tially that nothing has happened, because in Italy the patient
usually comes back to you whatever happens, and nobody has
come back.
Dr Koch. My final question pertains to cost. Another concern
for the use of erythropoietin is the cost of administration. You
were unable to demonstrate a cost benefit to the use of erythropoi-
etin in comparison with reduced red cell transfusion. There are data
to suggest that patients who received red cell transfusions have
a longer time on the ventilator postoperatively, an increased infec-
tion rate that needs treatment, and prolonged intensive care unit and
hospital length of stay. Can you speculate on whether or not if
you included the cost of morbid events related to transfusion in
your modeling, there would have been a cost benefit to the use of
erythropoietin?
Dr Weltert. I know from performed second-level analysis that
if we expanded the cost analysis to complications, this protocol
would be convenient, but I had to stick to the simpler approach
declared as the secondary end point. On further analysis,
however, the protocol sort of moved patients 1 unit down. So if
patients received 1 unit of blood, they were placed in a no trans-
fusion category and so on. The protocol failed to demonstrate
efficacy in the subset with more than 3 units of blood. There
was no difference in terms of length of stay in hospital. So I
can’t say there is direct evidence of cost enhancements in this
kind of analysis, but if we put everything together it will probably
become convenient, yes.
Dr Koch. Thank you.
Dr Beat Walpoth (Geneva, Switzerland). At least experimen-
tally there is some literature indicating that high-dose erythropoie-
tin in a peri-ischemic model is brain and heart protective. Did you
look at these issues in your large patient cohort?The Journal of Thoracic and CaDr Weltert. I know these studies. When I planned the study, I
tried to keep it as simple as possible with a clear primary end
point and a simple secondary end point. The studies in literature
usually fail to demonstrate statistically the evidence of associa-
tion. I didn’t want to get into that difficult topic, so I did not col-
lect these data. However, the risks of thrombosis and ischemia
are minimized by the inclusion criteria (patients with high hemat-
ocrit were excluded) and by the fact that every patient loses blood
after the operation exactly on the day of maximal bone marrow
output, thus lowering hematocrit and keeping it indirectly in
a safe range.
Dr R. Duane Davis (Durham, NC). Can you comment on what
you use for your antiplatelet therapy postoperatively, and how did
you assess for myocardial ischemic or infarction events?
DrWeltert.We followed the European guidelines for antiplate-
let medications and diagnosis of ischemic events. More specifi-
cally, we used 100 mg of acetyl salicylic acid since day 1 for the
patient without previous ischemic cardiac events, and we used an
association of aspirin and clopidogrel when myocardial infarction
or ischemia occurred in the 15 days before surgery.
Dr Patricia M. Cruchley (Kitchener, Ontario, Canada). Your
hemoglobin levels were quite high. Have you tried to separate out
your patients in each group to see if the patients who were anemic
received some benefit from the erythropoietin versus the whole
group with their hemoglobin level of 134 g/dL or whatever your
average was?
DrWeltert.Yes, absolutely. The subset of patients with a hemo-
globin less than 9 g/dL had the highest benefit from the protocol.
The protocol does not give a statistical significant advantage on
day 1. We collected the analysis, but I didn’t speak about that
because there was no difference. But it shows a difference on day
4. The difference is inversely proportional to the starting point.
So, yes, the subset who has the most benefit is the one starting
with low hemoglobin.rdiovascular Surgery c Volume 139, Number 3 627
